Interleukin 22 and its association with neurodegenerative disease activity

Wenjian Chen; Jianpeng Wang; Huaizhi Yang; Yuankai Sun; Bangjie Chen; Yuchen Liu; Yanxun Han; Ming Shan; Junfeng Zhan

doi:10.3389/fphar.2022.958022

Frontiers in Pharmacology (Sep 2022)

Interleukin 22 and its association with neurodegenerative disease activity

Wenjian Chen,
Jianpeng Wang,
Huaizhi Yang,
Yuankai Sun,
Bangjie Chen,
Yuchen Liu,
Yanxun Han,
Ming Shan,
Junfeng Zhan

Affiliations

Wenjian Chen: Department of Orthopaedics, Anhui Provincial Children’s Hospital, Hefei, China
Jianpeng Wang: School of First Clinical Medical College, Anhui Medical University, Hefei, China
Huaizhi Yang: School of First Clinical Medical College, Anhui Medical University, Hefei, China
Yuankai Sun: School of Pharmacy, Anhui Medical University, Hefei, China
Bangjie Chen: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
Yuchen Liu: Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Yanxun Han: Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Ming Shan: Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
Junfeng Zhan: Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

DOI: https://doi.org/10.3389/fphar.2022.958022
Journal volume & issue: Vol. 13

Abstract

Read online

It is worth noting that neuroinflammation is well recognized as a symptom of neurodegenerative diseases (NDs). The regulation of neuroinflammation becomes an attractive focus for innovative ND treatment technologies. There is evidence that IL-22 is associated with the development and progression of a wide assortment of NDs. For example, IL-22 can activate glial cells, causing them to generate pro-inflammatory cytokines and encourage lymphocyte infiltration in the brain. IL-22 mRNA is highly expressed in Alzheimer’s disease (AD) patients, and a high expression of IL-22 has also been detected in the brains of patients with other NDs. We examine the role of IL-22 in the development and treatment of NDs in this review, and we believe that IL-22 has therapeutic potential in these diseases.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords